Squarepoint Ops LLC Buys 18,522 Shares of Protalix BioTherapeutics, Inc. (NYSE:PLX)

Squarepoint Ops LLC increased its stake in shares of Protalix BioTherapeutics, Inc. (NYSE:PLX) by 33.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 73,940 shares of the company’s stock after buying an additional 18,522 shares during the quarter. Squarepoint Ops LLC owned 0.10% of Protalix BioTherapeutics worth $139,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PLX. Northern Trust Corp lifted its holdings in shares of Protalix BioTherapeutics by 1,299.4% during the fourth quarter. Northern Trust Corp now owns 731,742 shares of the company’s stock valued at $1,376,000 after acquiring an additional 679,451 shares during the period. Renaissance Technologies LLC lifted its holdings in Protalix BioTherapeutics by 17.0% during the 4th quarter. Renaissance Technologies LLC now owns 1,118,000 shares of the company’s stock valued at $2,102,000 after purchasing an additional 162,100 shares during the last quarter. Marshall Wace LLP bought a new position in shares of Protalix BioTherapeutics in the fourth quarter valued at approximately $192,000. Jane Street Group LLC raised its stake in shares of Protalix BioTherapeutics by 147.2% in the fourth quarter. Jane Street Group LLC now owns 113,616 shares of the company’s stock valued at $214,000 after acquiring an additional 67,664 shares during the last quarter. Finally, Prudential Financial Inc. bought a new position in shares of Protalix BioTherapeutics in the fourth quarter valued at approximately $68,000. 16.53% of the stock is owned by institutional investors.

Protalix BioTherapeutics Stock Up 3.9%

Protalix BioTherapeutics stock opened at $1.58 on Monday. Protalix BioTherapeutics, Inc. has a 12-month low of $0.82 and a 12-month high of $3.10. The stock has a market capitalization of $125.78 million, a price-to-earnings ratio of -12.15 and a beta of -0.21. The stock has a 50-day simple moving average of $2.22 and a 200 day simple moving average of $2.20.

Protalix BioTherapeutics (NYSE:PLX) last posted its quarterly earnings data on Friday, May 9th. The company reported ($0.05) earnings per share for the quarter. Protalix BioTherapeutics had a negative return on equity of 30.89% and a negative net margin of 21.03%. As a group, sell-side analysts anticipate that Protalix BioTherapeutics, Inc. will post 0.01 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Wall Street Zen downgraded Protalix BioTherapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, May 12th.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.